Dissecting the genomic complexity underlying medulloblastoma
David Jones, Natalie Jäger, Marcel Kool, Thomas Zichner, Barbara Hutter, Marc Sultan, Yoon‐Jae Cho, Trevor J. Pugh, Volker Hovestadt, Adrian M. Stütz, Tobias Rausch, Hans-Jörg Warnatz, Marina Ryzhova, Sebastian Bender, Dominik Sturm, Sabrina Pleier, Huriye Cin, Elke Pfaff, Laura Sieber, Andrea Wittmann, Marc Remke, Hendrik Witt, Sonja Hutter, Theophilos Tzaridis, Joachim Weischenfeldt, Benjamin Raeder, Meryem Avci, Vyacheslav Amstislavskiy, Marc Zapatka, Ursula Weber, Qi Wang, Bärbel Lasitschka, Cynthia C. Bartholomae, Manfred Schmidt, Christof von Kalle, Volker Ast, Chris Lawerenz, Roland Eils, Rolf Kabbe, Vladimı́r Beneš, Peter van Sluis, Jan Köster, Richard Volckmann, David Shih, Matthew J. Betts, Robert B. Russell, Simona Coco, Gian Paolo Tonini, Ulrich Schüller, Volkmar Hans, Norbert Graf, Yoo-Jin Kim, Camelia Monoranu, Wolfgang Roggendorf, Andreas Unterberg, Christel Herold‐Mende, Till Milde, Andreas E. Kulozik, Andreas von Deimling, Olaf Witt, E. Maaß, Jochen Rößler, Martin Ebinger, Martin U. Schuhmann, Michael C. Frühwald, Martin Hasselblatt, Nada Jabado, Stefan Rutkowski, André O. von Bueren, Dan Williamson, Steven C. Clifford, Martin G. McCabe, V. Peter Collins, Stephan Wolf, Stefan Wiemann, Hans Lehrach, Benedikt Brors, Wolfram Scheurlen, Jörg Felsberg, Guido Reifenberger, Paul A. Northcott, Michael D. Taylor, Matthew Meyerson, Scott L. Pomeroy, Marie‐Laure Yaspo, Jan O. Korbel, Andrey Korshunov, Stefan M. Pfister, Peter LichterNature2012 · DOI
Medulloblastoma is an aggressively growing tumour, arising in the cerebellum or medulla/brain stem. It is the most common malignant brain tumour in children, and shows tremendous biological and clinical heterogeneity. Despite recent treatment advances, approximately 40% of children experience tumour recurrence, and 30% will die from their disease. Those who survive often have a significantly reduced quality of life. Four tumour subgroups with distinct clinical, biological and genetic profiles are currently identified. WNT tumours, showing activated wingless pathway signalling, carry a favourable prognosis under current treatment regimens. SHH tumours show hedgehog pathway activation, and have an intermediate prognosis. Group 3 and 4 tumours are molecularly less well characterized, and also present the greatest clinical challenges. The full repertoire of genetic events driving this distinction, however, remains unclear. Here we describe an integrative deep-sequencing analysis of 125 tumour-normal pairs, conducted as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. Tetraploidy was identified as a frequent early event in Group 3 and 4 tumours, and a positive correlation between patient age and mutation rate was observed. Several recurrent mutations were identified, both in known medulloblastoma-related genes (CTNNB1, PTCH1, MLL2, SMARCA4) and in genes not previously linked to this tumour (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. RNA sequencing confirmed these alterations, and revealed the expression of what are, to our knowledge, the first medulloblastoma fusion genes identified. Chromatin modifiers were frequently altered across all subgroups. These findings enhance our understanding of the genomic complexity and heterogeneity underlying medulloblastoma, and provide several potential targets for new therapeutics, especially for Group 3 and 4 patients.
Introduction
Medulloblastoma is the most common malignant brain tumor in children, but it is not a single disease entity. It is categorized into four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. While WNT and SHH tumors are relatively well-understood, Groups 3 and 4—which present the greatest clinical challenges and the poorest prognoses—have remained "black boxes" regarding their genetic drivers. This study sought to identify the specific mutations, structural variations, and large-scale genomic changes that define these subgroups, particularly focusing on the drivers of aggressive tumor behavior.
Methods and Datasets
The study utilized an integrative "multi-omics" approach as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. The primary dataset consisted of 125 matched tumor-normal (germline) pairs from patients aged 0 to 17 years.
Sequencing: Researchers performed whole-genome sequencing (WGS) on 39 pairs, whole-exome sequencing (WES) on 21 pairs, and custom-capture sequencing of 2,734 genes on an additional 65 pairs.
Ploidy Analysis: A novel computational approach integrated copy-number aberrations with allele frequencies to predict tumor ploidy, validated using fluorescence in situ hybridization (FISH).
RNA-Seq: Used to confirm mutations and detect novel fusion genes and expression patterns.
Key Genomic Insights
Tetraploidy as an Early Driver
One of the most striking findings was that many Group 3 and 4 tumors are tetraploid, containing four sets of chromosomes. Tetraploidy was found in 54% of Group 3 and 40% of Group 4 tumors, compared to only 14% in WNT tumors. The data suggests this genome doubling happens very early in development, leading to massive genomic instability and large-scale copy number alterations.
Figure 1: Analysis of mutant allele frequencies in diploid vs. tetraploid tumors and the correlation between patient age and mutation burden.
The researchers found a positive correlation between a patient's age and the mutation rate, specifically within diploid tumors. This suggests that tumors in older children may arise from more differentiated cells that require more genetic "hits" to become malignant, whereas embryonic tumors might require fewer.
Subgroup-Specific Drivers and Fusions
The average somatic mutation rate was 0.52 per megabase (Mb). While lower than adult cancers, several recurrently mutated genes were identified, including DDX3X (enriched in WNT), CTDNEP1, KDM6A, and TBR1. Notably, alterations in chromatin modifiers were found across all subgroups, appearing in 36% of all cases.
Figure 2: Somatic SNV counts across the four molecular subgroups, highlighting the increased burden in SHH-p53 and WNT cases.
The study also identified the first-ever fusion genes in medulloblastoma, such as the DNAJB6-SHH fusion. These fusions often involve well-known oncogenes but occur through complex genomic rearrangements previously invisible to standard testing.
Conclusion and Future Directions
While this study provides a clearer map of Groups 3 and 4, these subgroups remain molecularly complex. The low number of "driving hits" in some cases suggests that epigenetic changes or non-coding mutations may play a larger role than expected.
Future work will focus on the clinical utility of tetraploidy as a prognostic marker. The authors suggest that drugs targeting the maintenance of tetraploidy, such as mitotic checkpoint kinase or kinesin inhibitors, could represent a rational therapeutic strategy for the most difficult-to-treat patients.
Summary updated
Abstract
Medulloblastoma is an aggressively growing tumour, arising in the cerebellum or medulla/brain stem. It is the most common malignant brain tumour in children, and shows tremendous biological and clinical heterogeneity. Despite recent treatment advances, approximately 40% of children experience tumour recurrence, and 30% will die from their disease. Those who survive often have a significantly reduced quality of life. Four tumour subgroups with distinct clinical, biological and genetic profiles are currently identified. WNT tumours, showing activated wingless pathway signalling, carry a favourable prognosis under current treatment regimens. SHH tumours show hedgehog pathway activation, and have an intermediate prognosis. Group 3 and 4 tumours are molecularly less well characterized, and also present the greatest clinical challenges. The full repertoire of genetic events driving this distinction, however, remains unclear. Here we describe an integrative deep-sequencing analysis of 125 tumour-normal pairs, conducted as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. Tetraploidy was identified as a frequent early event in Group 3 and 4 tumours, and a positive correlation between patient age and mutation rate was observed. Several recurrent mutations were identified, both in known medulloblastoma-related genes (CTNNB1, PTCH1, MLL2, SMARCA4) and in genes not previously linked to this tumour (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. RNA sequencing confirmed these alterations, and revealed the expression of what are, to our knowledge, the first medulloblastoma fusion genes identified. Chromatin modifiers were frequently altered across all subgroups. These findings enhance our understanding of the genomic complexity and heterogeneity underlying medulloblastoma, and provide several potential targets for new therapeutics, especially for Group 3 and 4 patients.
BibTeX
@inproceedings{jones2012dissecting,
author = {David Jones and Natalie Jäger and Marcel Kool and Thomas Zichner and Barbara Hutter and Marc Sultan and Yoon‐Jae Cho and Trevor J. Pugh and Volker Hovestadt and Adrian M. Stütz and Tobias Rausch and Hans-Jörg Warnatz and Marina Ryzhova and Sebastian Bender and Dominik Sturm and Sabrina Pleier and Huriye Cin and Elke Pfaff and Laura Sieber and Andrea Wittmann and Marc Remke and Hendrik Witt and Sonja Hutter and Theophilos Tzaridis and Joachim Weischenfeldt and Benjamin Raeder and Meryem Avci and Vyacheslav Amstislavskiy and Marc Zapatka and Ursula Weber and Qi Wang and Bärbel Lasitschka and Cynthia C. Bartholomae and Manfred Schmidt and Christof von Kalle and Volker Ast and Chris Lawerenz and Roland Eils and Rolf Kabbe and Vladimı́r Beneš and Peter van Sluis and Jan Köster and Richard Volckmann and David Shih and Matthew J. Betts and Robert B. Russell and Simona Coco and Gian Paolo Tonini and Ulrich Schüller and Volkmar Hans and Norbert Graf and Yoo-Jin Kim and Camelia Monoranu and Wolfgang Roggendorf and Andreas Unterberg and Christel Herold‐Mende and Till Milde and Andreas E. Kulozik and Andreas von Deimling and Olaf Witt and E. Maaß and Jochen Rößler and Martin Ebinger and Martin U. Schuhmann and Michael C. Frühwald and Martin Hasselblatt and Nada Jabado and Stefan Rutkowski and André O. von Bueren and Dan Williamson and Steven C. Clifford and Martin G. McCabe and V. Peter Collins and Stephan Wolf and Stefan Wiemann and Hans Lehrach and Benedikt Brors and Wolfram Scheurlen and Jörg Felsberg and Guido Reifenberger and Paul A. Northcott and Michael D. Taylor and Matthew Meyerson and Scott L. Pomeroy and Marie‐Laure Yaspo and Jan O. Korbel and Andrey Korshunov and Roland Eils and Stefan M. Pfister and Peter Lichter},
title = {{Dissecting the genomic complexity underlying medulloblastoma}},
booktitle = {Nature},
year = {2012},
doi = {10.1038/nature11284},
}